Figure 1.

Changes in clinical findings, laboratory findings, and capillary abnormalities, and the profile of T and B cell subset analysis before and after guselkumab treatment. Changes in clinical findings (A), laboratory findings (B), and capillary abnormalities (C) before and after guselkumab treatment and their representative photographs (D). The transition of each T and B cell subset before and after guselkumab treatment (E). Spots represent each patient. Lines connecting dots represent changes in the same patient. PASI: psoriasis area and severity index; mRTSS: modified Rodnan total skin thickness score; CRISS: combined response index for SSc; %FVC: percentage predicted forced vital capacity; %DLco: percentage diffusion capacity of the lung for carbon monoxide; FSSG: Frequency Scale for the Symptoms of GERD; WBCs: white blood cells; Hb: haemoglobin; PLT: platelets; SP-D: surfactant protein D; KL-6: Krevs von den Lungen-6; NFB: nailfold bleeding; Th: helper T cells; Tc: cytotoxic T cells; Th1, type 1 helper T cells; Th2,:type 2 helper T cells; Th17: type 17 helper T cells; SwBmem: switched memory B cells; NSwBmem: non-switched memory B cells; DN B: double negative B cells. The combination of each cell surface marker is as follows; T cells: CD3⁺; CD4⁺ T cells: CD3⁺CD4⁺; CD8⁺ T cells: CD3⁺CD8⁺; Treg: CD3⁺CD4⁺CD25⁺CD127⁺; Th17: CD3⁺CD4⁺CCR6⁺CXCR3^-; Th1: CD3⁺CD4⁺CCR6^-CXCR3⁺; Th2: CD3⁺CD4⁺CCR6^-CXCR3^–; B cells: CD19⁺; switched memory B cells: CD19⁺IgD^-CD27⁺; non-switched memory B cells: CD19⁺IgD⁺CD27⁺; naïve B cells: CD19⁺IgD⁺CD27^–; DN B cells: CD19⁺IgD^–CD27^–; IgG⁺ class switched memory B cells: CD19⁺CD27⁺IgG⁺; plasmablast: CD19⁺CD20^–CD38⁺; plasma cells: CD19⁺CD38⁺CD138⁺; transitional B cells: CD19⁺CD24⁺CD38⁺